Ocugen, Inc. OCGN
Set alert
At close · Oct 30
After hours · Oct 30, 7:56 PM ET
- YTD
- -47.95%
- 1 year
- -52.52%
- Open
- 0.746
- Prev close
- 0.7442
- Mkt cap
- 238.29M
- Vol
- 5.42M
- Avg vol
- 6.48M
- EPS
- -0.26
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.6909
- High
- 0.76
- Forward P/E
- -2.85
- Beta
- 3.77
- Short ratio
- 14.01
- Inst. own
- 27.53%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.92278
- 200-d avg
- 1.30
- 1y target
- 6.25
5D chart
Signals (110)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 4:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:05 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:10 PM | 2 days ago |
| RSI: Oversold | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:35 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:00 PM | 2 days ago |
| RSI: Oversold | Oct 30, 11:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:40 PM | 5 days ago |
| RSI: Oversold | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:50 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:40 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:05 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:55 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 6 days ago |
| RSI: Oversold | Oct 26, 1:40 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:20 PM | 6 days ago |
| RSI: Oversold | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
3 days ago globenewswire.com
Ocugen to Participate in Upcoming November Investor and Industry Conferences
MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today…
1 week ago globenewswire.com
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a…
-
2 weeks ago benzinga.com
Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Region
Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapiesExpands access…
2 weeks ago globenewswire.com
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced…
3 weeks ago prnewswire.com
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be…
3 weeks ago newsfilecorp.com
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the…
3 weeks ago globenewswire.com
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
MALVERN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to…
3 weeks ago benzinga.com
Transcript: Ocugen Q2 2026 Earnings Conference Call
Ocugen (NASDAQ:OCGN) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts…
1 month ago globenewswire.com
Ocugen to Participate in Upcoming Scientific Conferences
MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today…
1 month ago globenewswire.com
Ocugen to Participate in Upcoming October Investor and Industry Conferences
MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today…
-
1 month ago benzinga.com
Ocugen Receives Bahamas Regulator Provisional Approval For OCU400 Has Been Granted Approval And Priority Designation; The Company Will Supply OCU400 Through An EAP, With Goal Of Treating First RP Patient Within 90 Days
Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP)…
1 month ago globenewswire.com
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
MALVERN, Pa., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced…
1 month ago marketbeat.com
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive…
1 month ago seekingalpha.com
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical
Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet needs in ophthalmology. I assign OCGN a Buy rating, citing strong clinical data, upcoming pivotal…
1 month ago benzinga.com
What's Happening With Ocugen Stock Thursday?
Shares of Ocugen are remaining flat Thursday morning as investors continue to weigh disappointing interim clinical trial data.
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $9.5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $10 to $9.5.
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON)…
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
2 months ago zacks.com
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
-
2 months ago benzinga.com
Ocugen Announces First Patient Dosed In Global Phase 3 Registrational Trial Of OCU410, Modifier Gene Therapy Candidate For GA Secondary To Dry Age-Related Macular Degeneration
The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine…
2 months ago globenewswire.com
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced…
2 months ago globenewswire.com
Ocugen to Participate in Upcoming September Investor and Industry Conferences
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that…
2 months ago defenseworld.net
Brokerages Set Ocugen, Inc. (NASDAQ:OCGN) Price Target at $9.50
Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are presently covering the company, Marketbeat Ratings…
2 months ago marketbeat.com
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in…
2 months ago zacks.com
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
2 months ago marketbeat.com
Ocugen Q2 Earnings Call Highlights
Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an…
2 months ago seekingalpha.com
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago.
-
2 months ago benzinga.com
Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K Estimate
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 40 percent decrease over losses of $(0.05) per…
-
3 months ago benzinga.com
FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration
RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet need The designation could…
-
3 months ago benzinga.com
Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North Africa
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400
-
5 months ago benzinga.com
Canaccord Genuity Maintains Buy on Ocugen, Lowers Price Target to $11
Canaccord Genuity analyst Whitney Ijem maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $12 to $11.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
6 months ago benzinga.com
Full Transcript: Ocugen Q1 2026 Earnings Call
Full Transcript: Ocugen Q1 2026 Earnings Call
-
6 months ago benzinga.com
Ocugen Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $1.533M Beat $540.000K Estimate
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 20 percent decrease over losses of $(0.05) per…
6 months ago benzinga.com
GeneDx Holdings, Duolingo, Kosmos Energy And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Dow futures up 100 pts. Shares of GeneDx Holdings (WGS) down 39.2% after cutting FY26 sales guidance. Other stocks falling in pre-market trading.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
6 months ago benzinga.com
Ocugen Plans To Commence $115M Senior Notes Offering
Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer, subject to market…
-
7 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Ocugen, Raises Price Target to $10
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and raises the price target from $7 to $10.
7 months ago benzinga.com
Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls
Ocugen stock falls after Phase 2 OCU410 data for dry AMD trails interim results, despite lesion reduction.
-
7 months ago benzinga.com
Ocugen's 12-month Data From Phase 2 ArMaDa trial of OCU410 (AAV5-RORA) For Geographic Atrophy Secondary To Dry Age-related Macular Degeneration Demonstrates Statistically Significant Reduction In Lesion Growth
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22%…
-
7 months ago benzinga.com
Canaccord Genuity Initiates Coverage On Ocugen with Buy Rating, Announces Price Target of $12
Canaccord Genuity analyst Whitney Ijem initiates coverage on Ocugen (NASDAQ:OCGN) with a Buy rating and announces Price Target of $12.
7 months ago benzinga.com
Why Is Ocugen Stock Soaring Today?
Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target.
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
7 months ago benzinga.com
Serve Robotics Posts Upbeat Q4 Results, Joins Auna, Acacia Research And Other Big Stocks Moving Higher On Wednesday
Dow falls 200+ points as Serve Robotics Inc (NASDAQ: SERV) shares rise 16.2% on better-than-expected earnings and raised sales guidance.
7 months ago benzinga.com
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst ratings page. Analysts' thoughts on LGND stock.
-
7 months ago benzinga.com
Oppenheimer Initiates Coverage On Ocugen with Outperform Rating, Announces Price Target of $10
Oppenheimer analyst Leland Gershell initiates coverage on Ocugen (NASDAQ:OCGN) with a Outperform rating and announces Price Target of $10.
-
8 months ago benzinga.com
Ocugen Q4 EPS $(0.06), Inline, Sales $(193.000K) Miss $860.000K Estimate
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 20 percent decrease over losses of $(0.05) per share from the same period last…